Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis

• Status: Unknown status
• Trial end date: 2021-08-31
• Target enrollment: 0
• Participant gender: All

Summary

A randomized, placebo-controlled, double-blinded cross-over study evaluating and quantifying the effect of pyridostigmine on muscle strength and symptoms in Myasthenia Gravis (MG)

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aarhus
• Collaborator: Aarhus University Hospital
• Treatments: Pyridostigmine Bromide

Criteria

Inclusion Criteria:

• MG verified by a) anti-body, or b) single-fiber EMG and/or decrement on ENG.

Exclusion Criteria:

• Anti-MuSK

• Known cardio-pulmonary disease

• Known neuropathy

• Known myopathy

• Known malignant disease

• Pregnancy or breastfeeding

• Mechanic ileus, urinary tract obstruction, peritonitis

De-novo MG Eligibility Criteria

• MG diagnosis < 2 months, no prior antimyasthenic medications

Chronic MG Eligibility Criteria

• MG diagnosis > 1 year, and stable pyridostigmine dosis